Collaborations

[Abstract] Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study

Background: Recurrence after early-stage breast cancer (BC) is a challenge, occurring in ∼30% of patients (pts). Recurrences may arise …

[Abstract] Does liver tumor morphology predict outcomes after LDT, PRRT or captem?

Background: Patients with metastatic neuroendocrine tumor (NET) have multiple options for liver-directed therapy (LDT) and systemic …

[Abstract] LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes

Purpose: Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven clinical utility in platinum-sensitive breast, ovary, pancreas, …

[Abstract] CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Background: Exemestane is a second generation steroidal aromatase inhibitor (AI) used for the treatment of estrogen receptor (ER) …

[Abstract] Crossover from One Aromatase Inhibitor (AI) to Another in the Exemestane and Letrozole Pharmacogenetics (ELPh) Trial

Background: Tolerance of AI therapy can be poor due to treatment-emergent toxicities and can lead to early discontinuation …